TW1 <GO>TARGET WATCH2 <GO>MARKETLIVE
API

Sobi

Latest price
445.80 SEK
17/09/2026
Latest (2)
570.62 SEK
+28.00%
Upside
Aligned
AVG (11)
550.00 SEK
+23.37%
Upside
Aligned
SOBI
3 mo+23.37%11 price targets
6 mo+15.52%13 price targets
1 yr+15.52%14 price targets
Max 21 price targets
Deutsche BankDNB CarnegieSEBBarclaysDanske BankPareto SecuritiesBerenbergExane BNP ParibasHC WainwrightSB1 MarketsArctic
HealthcareDrug Manufacturers—Specialty & Generic

About The Company

Swedish Orphan Biovitrum (Sobi) is a pharmaceutical company with two focus areas: haemophilia and rare diseases. Sobi is a merger of Swedish Orphan and Biovitrum. The company has its premises in Karolinska Institutet Science Park in Solna.
Wikipedia

Latest Consensus

The average of the latest price targets from multiple analysts.

Consensus
570.62 SEK
Upside
+28.00%
Aligned2 houses · range 551.24 SEK–590.00 SEK
551.24 SEK590.00 SEK

line = latest price · dot = consensus

Latest price445.80 SEK

Three Month Consensus

The median of each house's latest target set within the last 90 days.

Consensus
550.00 SEK
Upside
+23.37%
Aligned11 houses · range 466.00 SEK–590.00 SEK · last 90 days
466.00 SEK590.00 SEK

line = latest price · dot = consensus

Latest price445.80 SEK

Insider Trades for Sobi

No insider trades for the selected period.

More Price Targets for Sobi

Analyst
Hit rate 58 %
Date
Sep 8

Analyst
Hit rate 63 %
Date
Sep 8

Analyst
Hit rate 55 %
Date
Aug 4

Analyst
Hit rate 61 %
Date
Jul 30

Date
Jul 29

Analyst
Hit rate 74 %
Date
Jul 21

Analyst
Hit rate 62 %
Date
Jul 17

Analyst
Hit rate 54 %
Date
Jul 17

Date
Jul 17

Analyst
Hit rate 56 %
Date
Jul 17

Analyst
Hit rate 57 %
Date
Jul 17

Analyst
Hit rate 49 %
Date
Jun 11

Analyst
Hit rate 51 %
Date
Mar 27

Analyst
Hit rate 63 %
Date
Jan 8

Analyst
Hit rate 67 %
Date
Jul -25

Analyst
Hit rate 59 %
Date
Apr -25

Analyst
Hit rate 56 %
Date
Apr -25

Analyst
Hit rate 63 %
Date
Oct -24

Analyst
Hit rate 71 %
Date
Feb -24

Date
Nov -23

Analyst
Hit rate 66 %
Date
Jul -23